Sup et al developed a prognostic score for patients with classical Hodgkin's disease which included immunohistochemical staining for bcl-2. This can help identify patients who may benefit from more aggressive management. The authors are from the Cleveland Clinic Foundation.
Parameters:
(1) immunohistochemical staining for bcl-2 (>= 10% of malignant cells stain at a level at least as intense as small lymphocytes)
(2) clinical stage
(3) age of the patient
|
Parameter |
Finding |
Points |
|
staining for bcl-2 |
not strong |
0 |
|
|
strong |
1 |
|
clinical stage |
I or II |
0 |
|
|
III or IV |
1 |
|
age in years |
< 45 years of age |
0 |
|
|
>= 45 years of age |
1 |
total score =
= SUM(points for all 3 parameters)
Interpretation:
• minimum score: 0
• maximum score: 3
• The higher the score the worse the prognosis.
|
Score |
Risk Group |
|
0 |
low |
|
1 |
intermediate |
|
2 or 3 |
high |
|
Risk Group |
Overall Survival at 5 Years |
Overall Survival at 10 Years |
|
low |
100% |
100% |
|
intermediate |
84% |
72% |
|
high |
56% |
41% |
from Figure 2, page 3777
|
Risk Group |
Failure Free Survival at 5 Years |
Failure Free Survival at 10 Years |
|
low |
96% |
96% |
|
intermediate |
69% |
69% |
|
high |
54% |
38% |
from Figure 2, page 3777
Specialty: Hematology Oncology
